P/B
3,1
NeuroOne Medical Technologies
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
$11.8M
Market Cap • 9/28/2026
2009
(17 years)
Founded
2012
(14 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
1,3
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,4
EPS
—
Market Cap
Market Cap
11,8M
EV
9,9M
EV/Revenue
1
EV/EBITDA
-1,3
EV/EBIT
-1,2
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-10,2%
Total Yield
-10,2%
Payout
0%
Retained Earnings
-84,4M
Profitability
Gross Margin
55,6%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
57%
Capex/Revenue
1,2%
Capex/D&A
46,2%
Capex/OCF
-1,6%
SBC/OCF
—
% PPE
6%
% Goodwill
0%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
34,9%
CAGR Op. Income 5Y
0,5%
CAGR Net Income 5Y
-1,1%
CAGR EPS 5Y
-21,6%
CAGR OCF 5Y
2,3%
Leverage
N.D./EBITDA
0,3
Debt/Equity
0%
Current Ratio
2,8
Quick Ratio
1,5
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!